About: Design of multi-epitope vaccine candidate against SARS-CoV-2: a in-silico study

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Design of multi-epitope vaccine candidate against SARS-CoV-2: a in-silico study Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Design of multi-epitope vaccine candidate against SARS-CoV-2: a in-silico study
Creator	Krupanidhi, S Peele, K Sai, A Srihansa, T Venkateswarulu, T
Source	Medline; PMC; WHO
abstract	The best therapeutic strategy to find an effective vaccine against SARS-CoV-2 is to explore the target structural protein. In the present study, a novel multi-epitope vaccine is designed using in silico tools that potentially trigger both CD4 and CD8 T-cell immune responses against the novel Coronavirus. The vaccine candidate was designed using B and T-cell epitopes that can act as an immunogen and elicits immune response in the host system. NCBI was used for the retrieval of surface spike glycoprotein, of novel corona virus (SARS-CoV-2) strains. VaxiJen server screens the most important immunogen of all the proteins and IEDB server gives the prediction and analysis of B and T cell epitopes. Final vaccine construct was designed in silico composed of 425 amino acids including the 50S ribosomal protein adjuvant and the construct was computationally validated in terms of antigenicity, allergenicity and stability on considering all critical parameters into consideration. The results subjected to the modeling and docking studies of vaccine were validated. Molecular docking study revealed the protein-protein binding interactions between the vaccine construct and TLR-3 immune receptor. The MD simulations confirmed stability of the binding pose. The immune simulation results showed significant response for immune cells. The findings of the study confirmed that the final vaccine construct of chimeric peptide could able to enhance the immune response against nCoV-19.
has issue date	2020-06-01(xsd:dateTime)
bibo:doi	10.1080/07391102.2020.1770127
bibo:pmid	32419646
has license	no-cc
sha1sum (hex)	defec48c714bf474bf4c1b74c6d6128035c5e241
schema:url	https://doi.org/10.1080/07391102.2020.1770127
resource representing a document's title	Design of multi-epitope vaccine candidate against SARS-CoV-2: a in-silico study
has PubMed Central identifier	PMC7284139
has PubMed identifier	32419646
schema:publication	J Biomol Struct Dyn
resource representing a document's body	covid:defec48c714bf474bf4c1b74c6d6128035c5e241#body_text
is schema:about of	named entity 'corona virus' named entity 'terms' named entity 'protein' named entity 'immune response' named entity 'Coronavirus' named entity 'effective' named entity 'vaccine' named entity 'validated' named entity 'pose' named entity 'ribosomal protein' named entity 'validated' named entity 'prediction' named entity 'strains' named entity 'vaccine' named entity 'confirmed' named entity 'trigger' named entity 'enhance' named entity 'vaccine' named entity 'glycoprotein' named entity 'immunogen' named entity 'CD8 T-cell' named entity '50S' named entity 'vaccine' named entity 'immune cells' named entity 'amino acids' named entity 'NCBI' named entity 'T-cell' named entity 'epitopes' named entity 'ribosomal protein' named entity 'protein-protein binding interactions' named entity 'allergenicity' named entity 'in-silico' named entity 'immunogen' named entity 'adjuvant' named entity 'capillary permeability' named entity 'loop regions' named entity 'vaccine' named entity 'half-life' named entity 'viral replication' named entity 'non-structural proteins' named entity 'epitopes' named entity 'High levels' named entity 'reticulocytes' named entity 'immune responses' named entity 'B-cell' named entity 'I-TASSER' named entity 'antigen' named entity 'non-structural protein' named entity 'epitope' named entity 'immune cells' named entity 'epitopes' named entity 'spike protein' named entity 'SARS-CoV-2' named entity 'PSIPRED' named entity 'viral proteins' named entity 'adjuvant' named entity 'LPS' named entity 'MERS' named entity 'host cells' named entity 'SARS-CoV-2' named entity 'lymphocyte' named entity 'ribosomal protein' named entity '1.2' named entity 'Ag3' named entity 'positive sense' named entity 'immune cell' named entity 'pneumocyte' named entity 'B-cell' named entity 'alleles' named entity 'host cell' named entity 'toxin' named entity 'immunization' named entity 'TLR-3' named entity 'Corona virus' named entity 'Nucleocapsid' named entity 'SARS-CoV-2' named entity 'peptides'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software